Philip Hemme

New #Doppelhelix episode with NanoTemper Technologies CEO Philipp Baaske out now! Philipp is one of the few founders I know who bootstrapped a deep tech company. In this episode, he tells his story of starting the company right after finishing his PhD and building a world-leading company in biophysical tools. We also take a deep dive into some of the company's technologies and the applications they are used for. If you have ever wanted to know more about the technical aspects of drug discovery and characterisation, this episode is for you! [Podcast in German] #biotech #drugdiscovery #biotools

37

7 Kommentare

𝗔𝗿𝗲 𝗩𝗛𝗛 (𝘀𝗶𝗻𝗴𝗹𝗲-𝗱𝗼𝗺𝗮𝗶𝗻 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀) 𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝗶𝗹𝘆 𝗽𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗹𝗲? Investing in new technologies always comes with the fear of not seeing the return you hope for. Especially for Life-Science companies that require big operational costs and investing capital. 𝗦𝗼, 𝗰𝗼𝘂𝗹𝗱 𝘁𝗵𝗲 𝗿𝗲𝗮𝗹 𝘃𝗮𝗹𝘂𝗲 𝗼𝗳 𝗩𝗛𝗛 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗯𝗲 𝗶𝗻 𝗶𝘁𝘀 𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝘁𝗼 𝗱𝗿𝗶𝘃𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗯𝘂𝗶𝗹𝗱 𝗳𝘂𝘁𝘂𝗿𝗲-𝗿𝗲𝗮𝗱𝘆 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗮𝘁 𝗮 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝗰𝗼𝘀𝘁? When we talk about VHHs, we’re not just talking about replacing traditional antibodies. VHH technology is not only about being “quick and cheap”. It is about being 𝗽𝗿𝗲𝗰𝗶𝘀𝗲, 𝘀𝗰𝗮𝗹𝗮𝗯𝗹𝗲, 𝗳𝗹𝗲𝘅𝗶𝗯𝗹𝗲, 𝗮𝗻𝗱 𝗿𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝗰𝗼𝘀𝘁𝘀 linked to maintenance and initial investments. How? 1. VHHs are 𝟭𝟬𝗫 𝘀𝗺𝗮𝗹𝗹𝗲𝗿 than conventional antibodies.  Think about the difference between a 𝘁𝗮𝗹𝗹 𝗵𝘂𝗺𝗮𝗻 𝗮𝗻𝗱 𝗮 𝗿𝗮𝘁 : 2m vs 20cm, so 10X size difference. Do you think you can reach the same places as the rat? 🐁🙃    ➡️ Their small size offers a competitive advantage in many niches, like penetrating tissues or crossing barriers where traditional antibodies struggle.     2. VHHs are 𝗲𝗮𝘀𝗶𝗲𝗿 𝘁𝗼 𝗺𝗼𝗱𝗶𝗳𝘆 𝗮𝗻𝗱 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗲. Their simple structure allows scientists to tweak them for specific tasks faster and more efficiently than traditional antibodies.    ➡️ They can be tailored for challenging targets or specific conditions, offering unmatched flexibility in research and therapeutic applications.     3. E.coli or yeasts used for production are easier to engineer and 𝗿𝗲𝗾𝘂𝗶𝗿𝗲 𝗹𝗲𝘀𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 compared to CHO systems.    ➡️This significantly lowers initial capital investment and operational costs, making VHH production more accessible and scalable for various applications.     4. VHHs are 𝗿𝗲𝗺𝗮𝗿𝗸𝗮𝗯𝗹𝘆 𝘀𝘁𝗮𝗯𝗹𝗲, 𝗲𝘃𝗲𝗻 𝗶𝗻 𝗲𝘅𝘁𝗿𝗲𝗺𝗲 𝗰𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀. Think of the difference between a cactus and an orchid.    ➡️ They can survive in harsh environments, such as higher/lower temperatures or pH, making them ideal for applications where traditional antibodies would degrade.    So, yes, the initial investment in VHH technology might be comparable to traditional methods, but what you’re really investing in is 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻, 𝗿𝗲𝗹𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆, 𝘀𝗰𝗮𝗹𝗮𝗯𝗶𝗹𝗶𝘁𝘆, and 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝘀𝘂𝗰𝗰𝗲𝘀𝘀. After all, isn’t that what profitability is all about? 😊 Phil. PS: I've launched EVOBody™, a unique platform allowing biotech leaders to develop single-domain antibody projects from concept to generation with minimal risk in only 6 weeks, for maximum impact. Apply for access to our program by clicking on 'Schedule a Meeting' under my profile.

71

5 Kommentare

Asking for a friend 😎 "Dear ChatGPT, what is Philipp famous for?" Philipp Baaske, co-founder and Co-CEO of NanoTemper Technologies, is renowned for his entrepreneurial spirit and significant contributions to the biotechnology and life sciences industries. He is particularly famous for: 1. Innovative Technology Development: Philipp Baaske has played a crucial role in the development and commercialization of cutting-edge biophysical instruments that have transformed approaches in drug discovery and molecular research. NanoTemper Technologies is known for its precision instruments like the Monolith and Prometheus, which are used globally in academic and pharmaceutical research to study molecular interactions. 2. Leadership in Biotechnology: Under his leadership, NanoTemper Technologies has grown from a university spin-off into a profitable and internationally recognized company. His vision has helped bridge the gap between academic research findings and practical, market-ready biotechnological applications. 3. Contributions to Scientific Community: Philipp is also recognized for his active role in fostering collaborations and knowledge exchange within the scientific community. He frequently engages in discussions and events that promote innovation and application in biotechnology and pharmaceutical sciences. 4. Entrepreneurial Success: His journey from starting NanoTemper in a university setting to leading a successful global company serves as an inspiration to many budding entrepreneurs in the biotech field, showcasing the potential of turning scientific expertise into successful business ventures. Philipp Baaske's impact extends beyond the technical innovations of his company to include his influence on industry standards and practices, making him a notable figure in the international biotech community. Funny and interesting to read what ChatGPT thinks about me. What would you ask for a friend? Life is better with humor 😂 #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔

81

25 Kommentare

https://colab.bayer.com/ The Sarcomatrix team is honored to accept the runner-up award from the BIO Europe Startup Showcase, presented by Bayer, which includes an invitation to attend the grand opening of the Bayer Co.Lab Berlin later this month. We extend special thanks to Dr. Ruth Shah, Head of Bayer Co.Lab Berlin, and her team for this wonderful opportunity and their warm invitation. Bayer Co.Lab is an innovative initiative by Bayer designed to empower biotech and life sciences startups by providing them with critical resources, expertise, and industry connections in a collaborative environment. The Co.Lab solution offers a comprehensive platform where startups can leverage Bayer’s infrastructure and support to accelerate their research and development efforts. Key features of the Bayer Co.Lab include access to state-of-the-art lab facilities, mentorship from industry leaders, and opportunities for strategic partnership with Bayer’s vast network. The program aims to streamline the innovation process for emerging companies, enabling faster progression from early-stage research to impactful, market-ready solutions. By offering support in regulatory navigation, clinical trial design, and go-to-market strategy, Bayer Co.Lab reduces traditional barriers to entry, fostering a community of forward-thinking companies ready to make a meaningful impact in healthcare and beyond. Bayer Co.Lab is ultimately a bridge for transformative ideas, positioning startups to advance their scientific discoveries with the backing of Bayer’s knowledge, resources, and global reach.

34

4 Kommentare

📊 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐁𝐢𝐨𝐄𝐮𝐫𝐨𝐩𝐞: 𝐓𝐡𝐞 𝐒𝐡𝐢𝐟𝐭𝐢𝐧𝐠 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 Today at BioEurope, new data reveals interesting changes in the biotech fundraising market. While the number of investment rounds is decreasing, the size of each round has grown significantly—reflecting a trend towards fewer but larger funding events. However, a notable funding gap remains between the U.S. and Europe, with U.S. investments almost double in size on average compared to those in Europe. This difference underlines both the challenge and the potential for European biotech to attract larger rounds and bolster innovation in the region. As we continue to navigate this changing landscape, how can we bridge this gap and foster growth within the European biotech ecosystem? Let's keep the conversation going on ways to drive global competitiveness and support biotech breakthroughs across borders. #BioEurope #Biotech #Fundraising #Investment #Innovation #LifeSciences #EuropeBiotech #FundingGaps

19

1 Kommentar

BioNTech’s VEGF Bispecific Strategy: Early Data and Future Prospects BioNTech has recently shared promising early survival data for its PD-L1xVEGF bispecific antibody, BNT327, in triple-negative breast cancer (TNBC)—an aggressive cancer subtype with limited treatment options. These results come on the heels of BioNTech’s $800M acquisition of Biotheus, which includes BNT327, demonstrating its commitment to advancing bispecific antibodies as a novel therapeutic approach. Key Results: In a China-based Phase 1b/2 trial, BNT327 combined with chemotherapy yielded a 12-month overall survival (OS) rate of over 80%, though the OS rate dropped to 69.7% at 18 months. Median progression-free survival (PFS) reached 13.5 months, slightly improving on earlier data. Objective response rate (ORR) was reported at 73.8%, a primary trial endpoint. Why It Matters: VEGF bispecific antibodies represent an emerging class of oncology treatments, combining immune modulation and anti-angiogenesis to target tumors more effectively. They’ve recently gained attention due to successes like Summit Therapeutics and Akeso’s VEGF bispecific outperforming Merck’s Keytruda in lung cancer. However, questions remain about their broader applicability and durability, particularly in overall survival. Future Directions: BioNTech is extending its research globally, with ongoing Phase 2 trials in TNBC across the US, UK, and Australia. Additionally, BNT327 is being tested in non-small cell lung cancer, showing a 57.8% ORR in EGFR-mutant patients. These trials will help determine if the positive signals from China translate to diverse patient populations. Strategic Context: The $800M acquisition of Biotheus underscores BioNTech’s intention to diversify beyond mRNA platforms, including its pivotal COVID-19 vaccine, to establish a stronghold in oncology. This move aligns with broader industry trends, as demonstrated by Merck’s $588M deal for a similar PD-1xVEGF bispecific candidate. The development of VEGF bispecifics highlights the increasing complexity of cancer treatment, offering hope for patients with challenging diagnoses like TNBC. If these early signals hold in larger trials, BioNTech could pioneer a new generation of targeted cancer therapies, contributing to the broader transformation of oncology care. More on the link below: https://lnkd.in/eSknqA_8

10

1 Kommentar

Last Friday, ATAI Life Sciences AG sold 2.66m shares of Compass Pathways resulting in proceeds of $16.1M as part of its ongoing efforts to manage its cash runway and to continue driving its fully owned programs: VLS-01 (DMT), EMP-01 (R-MDMA) and IBX-210 (Ibogaine).   atai continues to be a strong supporter of the excellent work of Compass and maintains high conviction in the ongoing COMP005 and COMP006 Phase 3 studies. And, as disclosed publicly, atai still owns approx. 10% of Compass of course!   In markets like this, you are sometimes forced to do trade-offs. In my view, atai selling approx. 1/3 of its Compass stake was better for shareholder value than potentially raising now on the atai level, at a share price I personally regard as extremely undervalued.   The trade-off also reflects atai’s strong confidence into its own, fully owned pipeline programs, especially for DMT (which fits into the 2-hour treatment window atai is targeting commercially), and hence its commitment to creating significant value for both patients and shareholders alike.

145

12 Kommentare

The last few days I've been attending SynBioBeta conference in San Jose, CA. Really cool innovations that are tackling big problems in health, industrial production, and climate. It was also AgFunder's AGM... some non-standard observations: 1- Venture markets are not back: it will not be a bounce, but a slow recovery 2- Smart startups are partnering with engineering/EPC firms earlier in their life. This is key to de-risk scale production from day 1. My first employer out of college Black & Veatch was a key partner in the growth of Tesla, and now they're active in the bio space 3- If you say you're AI, you better prove it. Nothing wrong with saying you're doing ML

15

I am excited to announce the upcoming launch of "The Proven Health-tech CEO" channels on Telegram and Whatsapp! They will be launched on Tuesday next week at 11am UK time, so watch this space! As a seasoned executive with a track record of guiding companies to over $1bn in valuation, I understand the importance of providing no-nonsense advice to founders seeking the best valuations for their startups. Stay tuned for valuable content packed with insights gleaned from my successful exits and company growth strategies. Plus, watch out for the launch of my Youtube channel featuring podcasts, interviews, and video content in the coming weeks. Recognizing the challenge of finding relevant content on social media, I will be creating a searchable website for business leaders to easily access and revisit valuable insights. Moreover, to stay updated on my latest content amidst algorithm changes, make sure to click the bell 🔔 on the top right of my profile to subscribe directly. Join me on this journey to scale your startups and achieve remarkable success! #TheProvenHealthTechCEO #StartupAdvice #BusinessGrowth Hassan Chaudhury HonFAPM Dr Rizwan Malik

104

27 Kommentare

The Impact of Specialized Investors on Startup Success. Across industries, startups are 1.2x more likely to achieve a successful IPO if their lead investor has strong expertise in the startup's sector. This is especially evident in biotech and medtech, where specialized VCs consistently outperform. Why? Deep domain knowledge allows these investors to more accurately assess startups, their growth potential, and their market fit, leading to smarter investments and stronger partnerships. For founders, choosing the right investor isn’t just about funding—it’s about aligning with expertise that can propel your company forward. Source: pitchbook. com #VC #Startups #Biotech #MedTech #InvestorInsights

6

New preprint from the Gero team showcases more evidence for the entropic theory of human aging. Link is in the comments! Great work by Peter Fedichev Kirill Denisov Jan Gruber

18

2 Kommentare

Early stage Biotech entrepreneur. Don't do the mistake of trying to do it all by yourself. Manage carefully your early stage seed/round A investment money by teaming up with a boutique CDMO. Scinai Bioservices is here to advance your project to the next catalyst. Take a read below:

12

You either die a solution provider or you live long enough to see yourself become a drug discovery company. Or do you?... - We present the first comprehensive map of the Omics Solution Provider landscape - As biology advances exponentially, new multi-omic technologies to read, write, and edit cells (genome, proteome, metabolome, or epigenome) emerge every week, rapidly increasing the level of complexity. Techniques that would have made the cover of Nature Biotech ten years ago are now standard in experimental protocols. Skills that once required an entire PhD and postdoc to master are now routinely expected from a first-year research associate. How are we supposed to keep exploring the farthest boundaries of biological possibilities if even the most basic discoveries depend on such complex and rapidly changing multi-omic technologies? Enter biological solutions providers. They play a crucial role in transforming cutting-edge biology into accessible solutions by abstracting these complex but essential tools into services, kits, or instruments. Within Omics, solution providers usually focus on genomics, proteomics, multi-omics, single-cell, or spatial biology. Whether it's a $100 whole genome sequencing, a detailed mapping of the spatial epigenome at single-cell resolution, the sequencing of a million cells simultaneously, or high-throughput cloning of plasmids into bacteria—impossible feats a decade ago—can now be accomplished in just a few hours with the help of Ultima Genomics, AtlasXomics, Fluent Biosciences, or Seqwell, respectively. We wanted to break down the Omics Solution Provider space into a digestible format that anyone can understand. Through numerous conversations with researchers, scientists, academics, and customers, we sought to create a market map. Going into this, we understood that any categories we grouped them into would be reductionist. Some companies fit well into multiple categories, and others don’t fit well into any of them. We did our best to balance usability and accuracy. We also looked into the dataset (DM and I’ll share) and found some really interesting insights. DM me (or comment your email) and i'll share.

368

52 Kommentare

Breaking News - Swiss Biotech Association Report 2024. Total number of Switzerland Biotech Companies at Ten (10) year High. Swiss lifescience exports up 400% in 24 years! Longevity, precision medicine, AI/Deep Learning likely to accelerate ALL further. quote "While exports from all other sectors combined grew by 81% in the twenty-five years from 1999 to 2023, the contribution of the life sciences sector grew by 400% over the same period (see Figure 1). " end-quote. https://lnkd.in/eeRbqTpX #investments, #switzerland, #pharma, #biotech, #venturecapital, #vc, #privateequity, #money, #gold, #forex, #fx, #cfa, #geneva, #zug, #zurich, #newyork, #stockmarket, #nyse, #money, #telaviv, #israel, #newyork, #capital, #alternativeinvestments, #trading, #stocks, #commodities, #healthcare, #lifescience, #innovation, #drugdevelopment, #longevity

7

1 Kommentar

If you have a moment, read my thoughts on the future of immune tolerance at Topas Therapeutics GmbH

28

🚀 Biggest Startup Funding Rounds Last Week🚀 #1: Metsera 💼 Sector: Biotech 💰 Funding: $290M 📝 Details: New York-based Metsera emerged from stealth mode with a whopping $290 million funding round led by Arch Venture Partners. Specializing in medicines for obesity and metabolic diseases, Metsera offers a range of oral and injectable therapies. #2: Rivos Inc. 💼 Sector: Semiconductor 💰 Funding: $250M 📝 Details: Santa Clara's Rivos secured over $250 million in a Series A-3 funding round, spearheaded by Matrix Capital Management. Their expertise lies in power-optimized chips tailored for data analytics and generative AI markets. #3: Ramp 💼 Sector: Fintech 💰 Funding: $150M 📝 Details: New York-based Ramp raised $150 million in their latest funding round led by Khosla Ventures and Founders Fund. With a valuation spike to $7.65 billion, Ramp focuses on streamlining corporate card and expense automation solutions. #4: Two Chairs 💼 Sector: Healthcare 💰 Funding: $72M 📝 Details: San Francisco's Two Chairs closed a $72 million Series C round, enhancing their behavioral health platform. Utilizing a proprietary algorithm, they match patients with suitable therapists, boasting a team of over 500 clinicians. #5: Cape 💼 Sector: Mobile 💰 Funding: $61M 📝 Details: Arlington-based Cape raised $61 million in their debut round led by A* and Andreessen Horowitz. Their focus on developing a privacy-first mobile network addresses prevalent security concerns in the telecom industry. #6: Avive Solutions Inc. 💼 Sector: Healthcare 💰 Funding: $57M 📝 Details: SF's Avive Solutions secured $56.5 million in growth equity financing led by Catalyst Health Ventures, Laerdal Million Lives Fund, and Questa Capital Management. They specialize in connected automated external defibrillators. #7: Asher Biotherapeutics 💼 Sector: Biotech 💰 Funding: $55M 📝 Details: South San Francisco's Asher Biotherapeutics closed a $55 million Series C round led by RA Capital Management. Their focus on targeted immunotherapies for various diseases shows promising potential. #8: Corner Therapeutics 💼 Sector: Biotech 💰 Funding: $54M 📝 Details: Watertown's Corner Therapeutics raised $54 million in funding led by Ziff Capital Partners. Specializing in immunotherapy, they're dedicated to developing innovative treatments. #9: Kontakt.io 💼 Sector: Artificial Intelligence 💰 Funding: $48M 📝 Details: New York-based Kontakt raised $47.5 million in funding led by Goldman Sachs Asset Management. They provide health systems with analytics on staff and patient movement within facilities. #10: Anvilogic 💼 Sector: Cybersecurity 💰 Funding: $45M 📝 Details: Palo Alto's Anvilogic closed a $45 million Series C round led by Evolution Equity Partners. Focusing on security information and event management, they strive to protect organizations from cyber threats. #startups #funding #startupfunding ---- Subscribe to my newsletter: newsletter.foundersbay.com

49

8 Kommentare

The innovation community outside Silicon Valley needs to “Feed the Seed” and invest resources in fostering Angel groups for delivering SAFEs and Notes to their budding startups.

1

Is it darkest before dawn? Pharma & Biotech are in a crisis. Is at least financing of certain Biotech areas getting better? Melanie Senior wrote this wonderful article about this topic. She finds that: - Clinical assets can attract more funding than ever. - Still looks bad for early stage companies with no proven assets. - ADC and Radiotherapeutics continue to outshine CGT this year. - Quality of Chinese assets is growing, Finally she concludes: “Given a dismal 2023, most agree with Novo Ventures’ Naveed Siddiqi that “things feel better now than this time last year.” How much better depends on where you’re sitting. The chosen few — biotechs and investors working in the right spaces, with the right experience — have more cash than ever and rich opportunities across the globe. The rest still face difficult times, as macroeconomic and geopolitical uncertainties continue to test investor confidence.” Here is the link: https://lnkd.in/dVrXsTtt What do you think about the financing situation in Biotech?

280

32 Kommentare

🔥 Ready to Ride the Bioinformatics Wave? Discover the Top 5 Game-Changing Startups! The bioinformatics landscape is ablaze with skyrocketing demand, creating fierce competition. Stay ahead of the curve by monitoring the rise of innovative startups reshaping the industry. Watch out for these top 5 startups set to revolutionize bioinformatics. Stay on top of the trends and gear up for what lies ahead.🚀 #Bioinformatics #Innovation #TechRevolution

3